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The twin arginine translocation (Tat) pathway transports fully-folded and assembled pro-
teins in bacteria, archaea and plant thylakoids. The Tat pathway contributes to the virulence
of numerous bacterial pathogens that cause disease in humans, cattle and poultry. Thus,
the Tat pathway has the potential to be a novel therapeutic target. Deciphering the Tat pro-
tein transport mechanism has been challenging since the active translocon only assembles
transiently in the presence of substrate and a proton motive force. To identify inhibitors of
Tat transport that could be used as biochemical tools and possibly as drug development
leads, we developed a high throughput screen (HTS) to assay the effects of compounds in
chemical libraries against protein export by the Escherichia coli Tat pathway. The primary
screen is a live cell assay based on a fluorescent Tat substrate that becomes degraded in
the cytoplasm when Tat transport is inhibited. Consequently, low fluorescence in the pres-
ence of a putative Tat inhibitor was scored as a hit. Two diverse chemical libraries were
screened, yielding average Z'-factors of 0.74 and 0.44, and hit rates of ~0.5% and 0.04%,
respectively. Hits were evaluated by a series of secondary screens. Electric field gradient
(Δψ) measurements were particularly important since the bacterial Tat transport requires a
Δψ. Seven low IC50 hits were eliminated by Δψ assays, suggesting ionophore activity. As
Δψ collapse is generally toxic to animal cells and efficient membrane permeability is gener-
ally favored during the selection of library compounds, these results suggest that secondary
screening of hits against electrochemical effects should be done early during hit validation.
Though none of the short-listed compounds inhibited Tat transport directly, the screening
and follow-up assays developed provide a roadmap to pursue Tat transport inhibitors.
Introduction
The targeting and transport of proteins across lipid membrane barriers is a fundamental pro-
cess in all cells that is essential for growth, development and homeostasis. In general, ~30–50%
of an organism's proteome is transported across or inserted into membranes by a variety of
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protein translocation machineries [1,2]. In bacteria, most extra-cytoplasmic proteins are trans-
ported across or into the cytoplasmic membrane by one of two major pathways, the general
secretory (Sec) pathway [3] or the twin arginine translocation (Tat) pathway [4].
The Tat pathway is unique because it transports fully-folded and assembled proteins (i.e.,
large, irregular-shaped macromolecules) without compromising the membrane's role as a bar-
rier to ions and metabolites [4]. In addition, it requires the presence of a proton motive force
(PMF) to function, but not nucleoside triphosphates (NTPs) [5,6]. In bacteria, only the electri-
cal field gradient (Δψ) component of the PMF is required for Tat transport [7]. The N-terminal
signal peptides (or ‘presequences’) of Tat precursor proteins contain a twin arginine consensus
motif (RR-motif)–hence the name Tat, for twin-arginine translocation [8]. In the bacterial
consensus motif, (S/T)RRxFLK, the arginine residues are almost invariant, whereas the other
amino acid residues occur with a frequency of> 50%. About 8% of E. coli cell-envelope pro-
teins (~30) are transported by the Tat machinery, and ~2/3 of these proteins contain prosthetic
groups, which are inserted into the proteins in the cytoplasm [9,10].
The E. coli Tat protein transport system contains four identified protein components, TatA,
TatB, TatC and TatE. Three of these proteins—TatA, TatB and TatE—are structurally similar,
and likely have a common origin [11]. They each have a single N-terminal transmembrane
domain and a C-terminal cytoplasmic domain [4,12]. TatC has six transmembrane domains
with both N- and C-termini facing the cytoplasm [13–15]. TatBC oligomers form the receptor
complex for Tat substrates [16,17]. The TatC X-ray structure reveals a glove-shaped pocket,
which can potentially accommodate a signal peptide hairpin that partially spans the bilayer
[15,18]. TatA and TatE form homo-oligomeric rings [19], suggesting that these proteins
can form translocation channels. The dominant model hypothesizes that TatA (or TatE) is
recruited to the TatBC-substrate complex in the presence of a PMF and forms the conduit nec-
essary for cargo transport [19,20]. Small molecules that perturb, inhibit or stabilize intermedi-
ates in this process are expected to be quite useful for deciphering the transport mechanism
and/or as in vitro or in vivo tools.
The Tat pathway is important for the pathogenicity of many bacteria [21]. In the case ofM.
tuberculosis, which is responsible for ~2 million global deaths annually due to tuberculosis, the
Tat pathway appears essential for bacterial survival [22,23]. Though the Tat machinery is not
essential for the growth of most bacteria, Tat deletion strains usually exhibit significant growth
defects such as enhanced susceptibility to external agents (antibiotics and detergents), and/or
reduced virulence [24–27]. The widespread increase in drug-resistant pathogens, especially
many multidrug-resistant strains, and the shortage of new antimicrobials emphasizes the
importance of discovering and characterizing new antibiotics and antibiotic targets [28]. In
animals, the Tat system has only been found in aspiculate homoscleromorph sponges [29].
Since the Tat machinery is absent from higher animals including humans, a drug that inhibits
protein export through the Tat machinery with high specificity is expected to be effective in
neutralizing or attenuating the pathogenicity of numerous bacteria, possibly without, or with
few, side effects.
We describe herein a high throughput screening approach to identify small molecule inhibi-
tors of Tat transport that can be used to assist with the characterization and elucidation of the
Tat transport mechanism and as lead compounds for the development of antibiotics to benefit
human health. This screen is based on a fluorescent Tat substrate that becomes degraded when
Tat transport is inhibited. We screened 51,600 compounds from a local library and 337,881
compounds from the NIH's Molecular Libraries Small Molecule Repository (MLSMR) at the
Broad Institute Probe Development Center (BIPDeC) (Cambridge, MA), a member of the
Molecular Libraries Probe Production Centers Network (MLPCN). The majority of lead com-
pounds obtained from the primary assay did not survive confirmation and dose response, and
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the remaining compounds did not survive follow-up biochemical assays. Compared with a pre-
vious approach [30], the strengths of our screening protocol are in vitro biochemical assays
that can verify whether the Tat machinery is a direct target of a putative inhibitor.
Results
Design of the HTS Assay
We developed a live cell-based high throughput screen (HTS) in which a C-terminal SsrA tag
promotes the cytoplasmic degradation of a pre-protein when Tat-dependent protein export is
inhibited or blocked. It was previously demonstrated that when Tat-dependent export of
spTorA-GFP-SsrA (which consists of the signal peptide of TorA fused to GFP with a C-termi-
nal SsrA tag) is impaired, the protein remaining in the cytoplasm is degraded by the ClpXP/
ClpAP protease system [31]. Since the fluorescence emission of GFP overlaps significantly with
the intrinsic fluorescence of Luria-Bertani (LB) media, we replaced the GFP domain with
mCherry, designating the new fluorescent Tat substrate as spTorA-mCherry-SsrA (Fig 1A and
1B, S1 Fig). The fluorescence emission from mCherry does not overlap with the intrinsic fluo-
rescence of LB media (Fig 1C).
The N-terminal signal peptide of TorA (spTorA) targets spTorA-mCherry-SsrA to the Tat
system for export to the periplasm. At the same time, the C-terminal SsrA tag promotes
ClpXP/ClpAP-dependent degradation of spTorA-mCherry-SsrA protein molecules in the
cytoplasm. Thus, there is competition between the export and degradation pathways. The total
cellular fluorescence arises from cytoplasmically-localized (and not degraded) mCherry protein
(predominantly the full-length precursor spTorA-mCherry-SsrA) and periplasmically-local-
ized mature protein (mCherry-SsrA). Due to the degradation of cytoplasmically-localized
spTorA-mCherry-SsrA, the total mCherry fluorescence observed for wild type cell cultures
should arise primarily from periplasmically-localized mCherry-SsrA. In contrast, when the Tat
machinery is absent or blocked (e.g., by an inhibitor), a significant decrease in fluorescence is
expected (Fig 1D).
Optimization of the Total mCherry Fluorescence Signal and Validation of
Substrate Design Properties
For maximum sensitivity in a HTS, a strong signal is needed. We examined the strength of the
mCherry fluorescence signal when the spTorA-mCherry-SsrA induction level was varied (0–
100 mM arabinose) in wild type (Tat+) and TatABC overproduced (Tat++) backgrounds. The
total cellular fluorescence plateaued at 50–100 mM arabinose, and TatABC overproduction
yielded an ~50% greater signal (Fig 2A). Cell fractionation and fluorescence microscopy analy-
sis confirmed that the major fluorescent species in the Tat++ (spTorA-mCherry-SsrA) strain
was periplasmically-localized mature protein (Fig 2B and 2C). Replacing the SsrA tag with a
6xHis-tag (yielding spTorA-mCherry-H6) resulted in an increase in cytoplasmic mCherry,
confirming that the SsrA tag promotes cytoplasmic degradation of the spTorA-mCherry-SsrA
protein. No periplasmic mCherry was observed in a Tat-deficient strain (ΔTat), confirming
that the spTorA-mCherry-SsrA protein was indeed targeted to and transported by the Tat sys-
tem (Fig 2B and 2C). No difference in total cellular fluorescence was observed if TatABC over-
production was induced at the same time as or 3 h before spTorA-mCherry-SsrA induction
(Fig 2D). The total cellular fluorescence plateaued ~12 h after spTorA-mCherry-SsrA produc-
tion was induced (Fig 2E). In summary, these data validate the spTorA-mCherry-SsrA protein
as a suitable fluorescence substrate for use in a HTS.
High-Throughput Screening for Tat Inhibitors
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Stability of the mCherry Fluorescence Signal
Since large HTSs require lengthy read times, we examined the stability of the mCherry fluores-
cence signal under Tat+ and Tat++ conditions. After 8 h of induction, spTorA-mCherry-SsrA
production was repressed by incubating cultures at 4°C (Fig 3A), which blocks cell growth, or by
the addition of 0.5% glucose (Fig 3B), which represses the arabinose promoter [32]. Both lower
temperature and glucose addition stabilized the total cellular fluorescence signal for at least ~12
h, although there were lags of ~2 and ~4 h before the fluorescence signal stabilized under low
Fig 1. Design of the HTS. (A) The fluorescent Tat precursor protein spTorA-mCherry-SsrA. The N-terminal TorA signal peptide (spTorA) targets the
fluorescent protein mCherry (PDB: 2H5W) to the Tat machinery for transport to the periplasm, and the C-terminal SsrA-tag promotes cytoplasmic
degradation of the protein. (B) Fluorescence spectra of LB media alone (black) and with cells producing spTorA-GFP-SsrA in the Tat++ background (green)
(EX = 485 nm). Tat++ denotes strain MC4100(DE3) in which TatABC is overproduced from the pTatABC-Duet1 plasmid (see Methods). (C) Fluorescence
spectra of LB media alone (black) and with cells producing spTorA-mCherry-SsrA (red) under the indicated conditions (EX = 587 nm). NaSCN collapses the
Δψ across the inner membrane. For (B) and (C), cells with (Tat++) or without (ΔTat) TatABC were induced with the indicated proteins and then incubated for
12 h at 4°C (ΔTat denotes strain MC4100ΔTatABCDE; see Methods for more details). (D) Design of the HTS assay. The SsrA tag on spTorA-mCherry-SsrA
promotes degradation of cytoplasmically-localized spTorA-mCherry-SsrA, and thus, periplasmically-localized mature Tat cargo (mCherry-SsrA) is the
dominant contributor to the total mCherry cellular fluorescence. In the ΔTat background, or in the presence of 30 mM NaSCN (positive control; simulated hit),
the total cellular fluorescence is lower, as shown in (C). Due to the competition between transport of mCherry to the periplasm by the Tat machinery and
degradation by the ClpXP/ClpAP protease system, low fluorescence in the presence of a putative Tat inhibitor was considered a hit. spTorA-mCherry-H6
(replacing the SsrA tag with a 6xHis-tag) is a control protein that is not degraded in the cytoplasm. OM = outer membrane; IM = inner membrane.
doi:10.1371/journal.pone.0149659.g001
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temperature and glucose repression conditions, respectively. These experiments identified a
timeframe in which we could read plates with minimal intra-plate and plate-to-plate variation.
Effect of Oxidative Phosphorylation Inhibitors on In Vivo Tat Transport
When screening for inhibitors via HTS, it is useful to include a known inhibitor as a positive
control. Since the Δψ is required for bacterial Tat transport [7], we tested whether various
Fig 2. Optimization of the Total mCherry Fluorescence Signal and Validation of Substrate Design Properties. (A) Effect of spTorA-mCherry-SsrA
induction levels on the total mCherry cellular fluorescence in wild type (Tat+; MC4100(DE3)) and TatABC overproduced (Tat++) backgrounds. The production
of spTorA-mCherry-SsrA was induced for 8 h at 25°C with the indicated concentrations of arabinose and the total mCherry cellular fluorescence was
determined (n = 3; EX = 587 nm, EM = 610 nm). TatABC was induced with 1 mM IPTG. (B) Cell fractionation. Cytoplasmic (C) and periplasmic (P) fractions
[60] of the indicated strains were analyzed after 8 h induction by SDS-PAGE and immunoblotting using anti-mCherry antibodies. For the top three gels, the
cells overproduced spTorA-mCherry-SsrA. For the bottom gel, the SsrA tag on spTorA-mCherry-SsrA was replaced with a 6xHis-tag (yielding spTorA-
mCherry-H6). Precursor (p) and mature (m) proteins are indicated. The * and ** identify what appears to be C-terminally truncated products. (C)
Fluorescence microscopy of the strains in (B). The mCherry proteins were induced at 25°C for 15 h with 2 mM arabinose. Cells were grown in fresh media for
an additional 5 h with no arabinose before imaging. More than 95% of cells showed a clear and dominating periplasmic localization of mCherry in the Tat++
strain versus ~70% for the Tat+ strain. No periplasmic mCherry was observed in the ΔTat strain, confirming that the spTorA-mCherry-SsrA protein was
indeed targeted to and transported by the Tat system. Replacing the SsrA tag with a 6xHis-tag resulted in an increase in the amount of cytoplasmic mCherry
(compare with Fig 2B), confirming that the SsrA tag promotes cytoplasmic degradation of the spTorA-mCherry-SsrA protein. Visually, about 80% of cells
showed noticeable cytoplasmic localization of spTorA-mCherry-H6. Bar = 1.3 μm. (D) Effect of TatABC pre-induction on the total cellular fluorescence of
mCherry. TatABC was induced 3 h prior to or simultaneously with spTorA-mCherry-SsrA (100 mM arabinose; n = 3). (E) Effect of induction time on the total
cellular fluorescence of mCherry. The spTorA-mCherry-SsrA protein was produced in the Tat++ background and the total mCherry cellular fluorescence was
obtained as in (A) (n = 3).
doi:10.1371/journal.pone.0149659.g002
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respiration inhibitors could be used to collapse the Δψ in vivo. In vitro, Tat transport is
completely inhibited by the addition of both nigericin and valinomycin, which collapse the
transmembrane pH gradient (ΔpH) and the Δψ, respectively [7]. High concentrations of nigeri-
cin and/or valinomycin (50 μM each) did not affect cell growth or mCherry fluorescence in cul-
ture (Fig 4A). This was unexpected since 2.5 μM of each these two ionophores are sufficient to
completely block Tat transport in vitro [7]. NaSCN alone completely inhibits in vitro Tat trans-
port, and, like valinomycin, NaSCN collapses the Δψ [7]. NaSCN (50 mM) reduced mCherry
fluorescence by ~40% without affecting growth of E. coli cultures (Fig 4A). Dose response data
showed that 30 mMNaSCN is sufficient to maximally reduce the mCherry fluorescence signal
without affecting cell growth (Fig 4B). Thus, NaSCN appears more effective than valinomycin
at inhibiting the Δψ in vivo, resulting in reduced Tat-dependent protein transport. Conse-
quently, NaSCN was used throughout our screens as a positive control (simulated hit). Sodium
azide is an inhibitor of cytochrome bo3, the terminal oxidase in the aerobic respiratory chain of
E. coli [33–35]. As expected, azide inhibited cell growth and decreased the mCherry fluores-
cence signal by similar amounts (Fig 4A).
Sensitivity of Fluorescence Detection on Plates
We next tested whether cellular mCherry fluorescence could be detected at reasonable cell densities
after growth in 384-well plates. Tat++ cells producing spTorA-mCherry-SsrA were serially diluted
into 384-well plates and incubated at 25°C for 8 h. Dose-dependent absorbance (due to light scat-
ter) and fluorescence signals were obtained. Under uninduced conditions, the fluorescence signals
were negligible, but cell densities were unaffected, as expected. Purified spTorA-mCherry yielded a
dose-dependent fluorescence signal and negligibleA500, also as expected (Fig 4C). These results
demonstrated a detectable range of cellular mCherry fluorescence signals on plates.
Outline of the HTS Assay
Having obtained the calibration and validation data described in the previous sections, we next
established the protocol for the HTS. Details are provided in the Materials and Methods
Fig 3. Stability of the mCherry Fluorescence Signal. (A) Stability of the total cellular fluorescence after transfer to 4°C. Cells producing spTorA-mCherry-
SsrA under Tat+ or Tat++ conditions were incubated at 25°C for 8 h, and then transferred to 4°C to inhibit growth. The total mCherry cellular fluorescence was
monitored periodically (n = 3). (B) Stability of the total cellular fluorescence after glucose addition. The total cellular fluorescence was quantified as in (A),
except that spTorA-mCherry-SsrA production was repressed by addition of 0.5% glucose after 8 h of growth. Growth was continued at 25°C (n = 3). These
data demonstrate that the intensity of the mCherry fluorescence signal can be maintained at a constant value for long time periods, thereby providing
consistency when reading many HTS plates.
doi:10.1371/journal.pone.0149659.g003
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section. Here, we briefly summarize the assay. A single colony of E. coli strain MC4100(DE3)
containing plasmids encoding TatABC and spTorA-mCherry-SsrA was inoculated into LB and
grown overnight. The next morning, cells were transferred to fresh media, the production of
TatABC and spTorA-mCherry-SsrA was induced, and cultures were aliquoted onto plates with
Fig 4. Effect of Oxidative Phosphorylation Inhibitors on In Vivo Tat Transport and Sensitivity of Fluorescence Detection on Plates. (A) Effect of
oxidative phosphorylation inhibitors on cell growth and mCherry fluorescence under Tat++ conditions. Cells producing spTorA-mCherry-SsrA under Tat++
conditions were grown at 25°C for 8 h in the presence of the indicated respiratory inhibitors. After overnight incubation at 4°C, optical densities (upper panel;
A500) and total mCherry cellular fluorescence intensities (lower panel; EX = 587 nm, EM = 610 nm) were measured (n = 3). Nigericin (N; 50 μM) is a H
+/K+
exchanger, which collapses the ΔpH gradient. Valinomycin (V; 50 μM) is a K+ ionophore, which collapses the Δψ. NaSCN (SCN; 50 mM) collapses the Δψ.
NaN3 (N3; 0.1%) inhibits the cytochrome bo3 terminal oxidase. (B) Effect of NaSCN concentration on cell density and total mCherry cellular fluorescence.
Measurements were made after incubating cells overnight at 4°C (n = 3). (C) Calibration and sensitivity of mCherry fluorescence detection in 384-well plates.
Overnight cultures of E. coliMC4100(DE3) cells were diluted to A500 = 0.25, 0.2, 0.15, 0.10 and 0.05, and aliquoted into 384-well plates. The spTorA-
mCherry-SsrA and TatABC proteins were induced together or neither were induced, as indicated. The cells were incubated at 25°C for 8 hours, and stored
overnight at 4°C. Optical densities (upper panel) and mCherry fluorescence intensities (lower panel) were determined with a BMG Polarstar Omega plate
reader (at 500 nm for absorbance; EX = 584 nm, EM = 620 nm for fluorescence). For comparison, the absorbance and fluorescence intensities from purified
spTorA-mCherry-H6 (30, 25, 20, 15, 10 and 5 nM) are also shown (n = 3 plates, 16 wells/plate). (D) Simulated hits on 384-well plates. Using the approach
described in (C), cells (A500 = 0.15) were grown on plates under the indicated conditions, and then fluorescence intensities were measured. spTorA-mCherry-
SsrA was used for conditions II-IV. spTorA-mCherry-H6 was used for a minus SsrA control (I; 100%). The SsrA tag decreased the mCherry fluorescence
intensity (II; 63±14%), consistent with a decrease in cytoplasmic mCherry concentration due to SsrA-dependent degradation. A further decrease in mCherry
fluorescence intensity was observed in Tat-deficient cells (ΔTat) (III; 41±6%) and in the presence of 30 mMNaSCN (IV; 36±14%), consistent with enhanced
cytoplasmic degradation due to inhibition of export to the periplasm (n = 3 plates, 16 wells/plate).
doi:10.1371/journal.pone.0149659.g004
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test compounds. NaSCN was included in control wells to simulate a hit. Cells were grown for 8
h, followed by incubation at 4°C overnight, and then read the next day. Setting the total cellular
fluorescence obtained with spTorA-mCherry-H6 under Tat++ conditions to 100%, spTorA-
mCherry-SsrA yielded a total cellular fluorescence signal of 63±14%, consistent with SsrA-
induced degradation of the mCherry protein. The total cellular fluorescence was further
reduced to 36±14% in the presence of 30 mMNaSCN (simulated hit), and to 41±6% in the
absence of TatABC, verifying the Δψ- and Tat-dependence of the fluorescence signal (Fig 4D).
The Local HTS
Preliminary HTS testing and optimization, initial small test screens, and a HTS of 51,600
diverse synthetic compounds were performed in the laboratory of one of us (James Sacchet-
tini). A sample 384-well plate from this local HTS is shown in Fig 5A. The edge columns con-
tain DMSO (−; negative control) and 30 mMNaSCN (+; positive control). Compounds were
tested at 5 or 20 μM. In this HTS, all plates were scanned for both cell growth (A500) and
mCherry fluorescence (Fig 5A and 5B). The control wells on each plate were used to calculate
the Z'-factor [36] for each plate, which provides an assessment of the performance of the assay
on each plate. The average Z'-factor was 0.74±0.09 (Fig 5C; n = 162 plates), indicating a robust
HTS assay. Some edge effects were observed (e.g., see Fig 5B), likely from uneven aeration or
heating across the plate during the growth incubation period, but these did not interfere with
hit calling.
Three categories of non-baseline outputs were identified. The first was “low cell density”, the
expected signature for growth inhibitors (77 compounds, 0.15% of total). The second category
was “high fluorescence and unchanged cell density”, which was expected for fluorescent com-
pounds, compounds that enhanced Tat translocation, compounds that increased transcription
of the spTorA-mCherry-SsrA mRNA, and compounds that inhibited the ClpXP/ClpAP prote-
ase system that recognizes the SsrA tag (208 compounds, 0.41% of total). The third category
was “low fluorescence and unchanged cell density”, the expected signature for true Tat inhibi-
tors. Compounds exhibiting this signature were considered “hits” (249 compounds, 0.48% of
total).
Hits were defined as having a 20% decrease in mCherry fluorescence, compared with the
NaSCN control (100%). The first 12,800 compounds (plates 1–40) were screened using 5 μM
of each test compound, yielding a hit rate of 0.016%. This was considered a low hit rate, so
the remaining compounds in the library (38,800 compounds, plates 41–162) were assayed at
20 μM, increasing the hit rate to 0.63%. The median fluorescence decrease for hits was 65%
(Fig 5D). The 249 hits were re-assayed via dose response (Fig 6), which yielded 78 surviving
compounds.
The Broad Institute Probe Development Center (BIPDeC) HTS
The validated 384-well HTS assay was transferred from the Texas A&MHealth Science Center
to the BIPDeC in order to screen the NIH’s Molecular Library Small Molecular Repository
(MLSMR) collection of compounds. Approximately 20% of the compounds in the local chemi-
cal library were in common with the MLSMR collection at the time of screening. The HTS
assay was adapted to run on the Broad’s high throughput screening system, which required fur-
ther miniaturization to run in a 1536-well format. To make the primary assay run more effi-
ciently, only the mCherry fluorescence was read, compared to the dual read done for the
384-well assay. From assay development and adaptation experiments, it was determined that
glucose addition after the 8 h induction period followed by an overnight incubation at 4°C
yielded a better signal-to-background ratio. The assay was validated using the MLSMR
High-Throughput Screening for Tat Inhibitors
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validation set, a small, ~2,000 compound collection composed of known bioactive compounds.
The validation run showed strong statistics with an average signal-to-background ratio of 12.9,
and an average Z'-factor [36] of 0.86 (data not shown).
Following validation, 337,881 compounds from the MLSMR collection were screened at
10 μM in duplicate using the adapted primary assay (Fig 7A). Tat translocation yield was
assessed by the intensity of mCherry fluorescence. Raw fluorescence values were normalized to
the average negative (DMSO only) and positive (30 mMNaSCN) controls on each plate. The
average Z'-factor was 0.44±0.23 (Fig 7B; n = 538 plates). A mean activity score was calculated
Fig 5. Sample Data from the Local HTS, Z'-factor Summary and Hit Summary. (A) Optical density (left panel; A500) and fluorescence intensity (right
panel; EX = 584 nm; EM = 620 nm) values from a typical local HTS plate obtained under Tat++ conditions. DMSO only (columns 2 and 23) and 30 mM
NaSCN (columns 1 and 24) controls are identified as − and +, respectively. (B) Graphical representation of the optical density (black) and fluorescence
intensity (red) values for each well of the plate shown in (A). A potential Tat inhibitor (well G-14) and growth inhibitor (well J-22) are identified by red and black
arrows, respectively. These intensity signatures are detectable in the raw data images in (A). (C) The Z'-factor for each plate from the local HTS. (D)
Fluorescence intensity distribution of compounds with the intensity signatures expected for a Tat inhibitor (see text). The percent fluorescence decrease is
normalized to the 30 mMNaSCN positive control (100%) and the DMSO control (0%).
doi:10.1371/journal.pone.0149659.g005
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by averaging the fluorescence decrease observed for the two replicates of each test compound.
Active compounds were defined as those compounds with a mean activity score 50 (50%
reduction in fluorescence, normalized to the NaSCN and DMSO controls). According to this
definition, 123 compounds were active (0.04% of the total screened). An additional 1,263 com-
pounds were labeled as inconclusive, defined as those for which 1 of the 2 replicates had an
activity score 50 (PubChem BioAssay AID 488895).
The active and inconclusive compounds were then reviewed for chemical intractability,
and any compounds determined to be unsuitable for follow-up chemistry were removed from
consideration. From this analysis, 1,256 compounds were reordered from the MLSMR for
retesting with the primary assay at various concentrations. Of these compounds, 48 yielded an
IC50< 20 μM (PubChem BioAssays AID 504941 and 651752). The 1,256 compounds were
also tested in a counter assay to identify non-specific bacterial inhibitors, which would show
false positive responses in the primary assay. Bacterial viability was assayed using the Bac-
TiterGlo (Promega) reagent using the same conditions as the primary assay, except without
the addition of induction reagents. From this analysis, 309 compounds exhibited > 20% inhi-
bition of bacterial growth (PubChem BioAssays AID 504843 and 651750). Based on the retest,
counter-assay and a chemical suitability analysis, 35 potential inhibitors of Tat translocation
Fig 6. Sample Dose Response Data for Hits from the Local HTS. (A) Optical density (left panel) and fluorescence intensity (right panel) values for a
typical local HTS dose response plate obtained under Tat++ conditions. DMSO only (columns 2 and 23) and 30 mMNaSCN (columns 1 and 24) controls are
identified as − and +, respectively. Compound concentrations are given at the top of each column. Note that there are two different compounds per row. Dose
response plates were run in duplicate. (B) Graphical representation of the values for the plate shown in (A).
doi:10.1371/journal.pone.0149659.g006
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were identified. These compounds were sourced from dry powders for additional retesting
and secondary analysis.
Secondary Screening: In Vitro Tat Transport Assays
Hits from the primary screen could include false positives for a variety of reasons. Hit com-
pound effects on the spTorA-mCherry-SsrA reporter that would result in a reduced mCherry
fluorescence signal include: i) a folding deficiency (i.e., which does not allow maturation of the
mCherry fluorophore); ii) inhibition of transcription or translation; and iii) increased SsrA-
dependent degradation (i.e., degradation instead of transport). In addition, Tat-dependent
transport requires a Δψ [7]. Therefore, compounds that inhibit PMF generation would be indi-
rect inhibitors of Tat-dependent transport. In contrast, our goal was to identify molecules that
inhibited Tat transport by directly binding to Tat proteins. Additional screens were therefore
required to verify whether hit compounds interacted specifically with Tat proteins.
To directly test for inhibition of Tat transport, a gel-based in vitro Tat transport assay was
performed using pre-SufI, an authentic Tat precursor protein [7]. In short, this assay consists
of incubating a Tat substrate and a Δψ-generating energy source with inverted membrane vesi-
cles (IMVs) containing overproduced TatABC, digesting remaining external protein with a
protease, and then analyzing via SDS-PAGE. This assay was run twice using NADH and ATP
(if warranted) as energy sources to generate the necessary Δψ. NADH generates a Δψ using
respiratory proteins (i.e., the NADH dehydrogenase and cytochrome bo3 ubiquinol oxidase
complexes [35]) and ATP generates a Δψ by reversal of ATP synthase [37]. A true Tat inhibitor
Fig 7. The BIPDeC HTS and Z'-factor Summary. (A) Activity results for the 337,881 compounds screened in the BIPDeC HTS. Active, inconclusive, and
inactive activity scores are defined in the text. (B) The Z'-factor for each plate from the BIPDeC HTS.
doi:10.1371/journal.pone.0149659.g007
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would survive both assays. In contrast, a respiration inhibitor is expected to reduce Tat trans-
port when only one of the two energy sources is used (except for an ionophore).
The criterion for surviving the in vitro Tat transport assays was visible inhibition of Tat
transport. Of the 78 compounds surviving the local HTS assay, 7 compounds (S2A–S2G Fig)
survived the in vitro Tat transport assay with NADH (Fig 8A). Of these 7 compounds, 6 sur-
vived the ATP-dependent Tat transport assay (Fig 8B). Based on its elimination by the ATP-
dependent assay, compound 55JS (N-(4,7-Dioxo-4,7-dihydro-2,1,3-benzoxadiazol-5-yl)acet-
amide) appears to affect some step of aerobic respiration between NADH and O2. Since this
compound is a quinone (Fig 8C), a likely possibility is that it interacts with the quinone binding
site on NADH dehydrogenase [38,39].
Of the 35 compounds surviving the BIPDeC's HTS assay, bacterial growth assay and chemi-
cal evaluation, 2 compounds (S2H and S2I Fig) survived the NADH- and ATP-dependent Tat
transport assays (Fig 9).
Secondary Screening: Δψ Assay
Hit compounds surviving the in vitro Tat transport assay screens could be general Δψ inhibi-
tors (ionophores), as both NADH and ATP generate the Δψ necessary for Tat transport. Since
our current assay to measure Δψ requires ~20 times more test compound than the Tat trans-
port assays, we reserved this assay for last. The presence of a Δψ was determined by measuring
oxonol VI fluorescence [7]. For all 8 hit compounds that survived initial secondary screening,
we tested their dose dependent effect on the Δψ, on NADH-dependent in vitro Tat transport
efficiency, and on the fluorescence signal recovered from our primary HTS assay (live cell
assay). An example of such an analysis is shown in S3 Fig. The IC50's calculated from these data
indicate that all surviving hit compounds, except compound 18NIH, collapse the Δψ (Table 1),
and this explains their ability to inhibit Tat transport. Initially, compound 18NIH (Broad Insti-
tute ID: BRD-A27765931-001-04-0) yielded promising results, as it did not collapse the Δψ
across IMVs, and yet it did inhibit in vitro Tat transport during early trials (S4 Fig). However,
these results could not be reproduced consistently. Out of 22 independent assays by three dif-
ferent people, compound 18NIH inhibited Tat transport 12 times. The conflicting results seem
more likely to arise from differences in IMV preparations rather than decomposition of or
impurities in the samples of compound 18NIH.
Effect of Pseudomonas aeruginosa Tat Inhibitors on E. coli Tat Transport
The two compounds N-phenylmaleimide and Bay 11–7082 were recently identified as inhibi-
tors of the Pseudomonas aeruginosa Tat machinery as a result of high throughput screening
[30]. We tested the effect of both compounds on transport by the E. coli Tat system. Both N-
phenylmaleimide and Bay 11–7082 inhibited E. coli growth under Tat++ conditions (S5 Fig).
Both compounds also inhibited synthesis of spTorA-mCherry-SsrA, though this appears to be
a consequence of growth inhibition. Most importantly, neither compound affected in vitro E.
coli Tat transport, and thus, we conclude that these compounds are not E. coli Tat transport
inhibitors (S5 Fig).
Both N-phenylmaleimide and Bay 11–7082 chemically react with cysteines [40]. There is
only one cysteine found in the P. aeruginosa Tat machinery, C208 of TatC. However, this resi-
due is buried within the TatC structure [15], and thus, it seems unlikely that it can be modified
by these reagents. Alternatively, if these reagents inhibit P. aeruginosa Tat transport by non-
covalent binding interactions with Tat proteins, our data indicate that such interactions are not
conserved between E. coli and P. aeruginosa.
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Discussion
A high throughput screening approach suitable for identifying small molecule inhibitors of the
E. coli Tat protein transport system was developed. The strengths of the reported approach
include: 1) an average Z'-factor> 0.7 (under the right screening conditions), which indicates a
robust HTS assay that need not be run in duplicate [36]; 2) a live cell primary HTS, enabling
early assessment of in vivo activity; 3) a hit rate ~0.5%, indicating selectivity; and 4) a series
Fig 8. Effect of Hits from the Local HTS on In Vitro Tat Transport. (A) Tat transport assays of pre-SufI using NADH to generate a Δψ. Inverted membrane
vesicles (IMVs; A280 = 5.0), the fluorescent substrate pre-SufI-IAC
Atto565 (90 nM), and NADH (4 mM) were incubated at 37°C for 30 min with DMSO (control)
or with hit compound (20 μM). Samples were treated with the protease proteinase K, run on SDS-PAGE, and analyzed by in-gel fluorescence imaging.
Assays were run in duplicate. Band intensity corresponds to the amount of protein transported into the IMV lumen. The following 7 compounds survived this
screen: 1JS, 51JS, 55JS, 111JS, 181JS, 202JS, and 140JS (boxed in red). (B) Tat transport assays of pre-SufI using ATP to generate a Δψ. All 7 compounds
surviving the screen in (A) were tested using a Tat transport assay performed identically to those in (A) except that ATP (1 mM) was used in place of NADH.
Compound 55JS was eliminated by this assay—the other 6 compounds survived (boxed in red). (C) Chemical structure of compound 55JS, N-(4,7-Dioxo-
4,7-dihydro-2,1,3-benzoxadiazol-5-yl)acetamide. The quinone structure suggests NADH dehydrogenase as a possible target, leading to inhibition of Tat
transport when using NADH as the energy source (A), but not when ATP is used (B).
doi:10.1371/journal.pone.0149659.g008
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of in vitro follow-up screens/assays that enable direct evaluation of hit activity against the target
system. Additional assays are available that would enable further in vitro characterization of
compound binding properties and the site of action [7,41]. Unfortunately, despite screening
~380,000 compounds, no inhibitors that bind directly to Tat proteins were identified. Based
on the in vitro follow-up assays, 7 hit compounds inhibit Tat transport by collapsing the Δψ,
one compound (55JS) inhibits Δψ generation by NADH (possibly by inhibiting NADH dehy-
drogenase), and one compound (18NIH) yielded irreproducible results. In addition, the two
Fig 9. Effect of Hits from the BIPDeC HTS on In Vitro Tat Transport. (A) & (B) Tat transport assays as in
(A) and (B) of Fig 7, respectively, using hit compounds from the BIPDeC HTS. Hit compound concentrations
of 100 μMwere used to maximize Tat transport inhibition, as the effects of a lower concentration (20 μM)
were not very pronounced (data not shown). Compounds 18NIH and 21NIH survived the NADH-dependent
assay (A) and were tested in the ATP-dependent assay (B). Both of these compounds survived the ATP-
dependent assay. Surviving compounds at each stage are boxed in red.
doi:10.1371/journal.pone.0149659.g009
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compounds previously identified as P. aeruginosa Tat machinery inhibitors were shown not to
be E. coli Tat inhibitors.
Since the proton motive force drives a wide range of crucial processes, E. coli are not
expected to divide and multiply if they cannot maintain a membrane potential across the cyto-
plasmic membrane. How, then, did 7 hits survive the HTS and in vivo growth screen, only to
be eliminated in follow-up assays as compounds that collapse the Δψ? Similarly, why do the
ionophores nigericin and valinomycin inhibit Tat transport in vitro [7] but not in vivo (Fig
4A)? Efflux pumps, poor cell permeability of the cell envelope, or reduced efficacy due to bind-
ing interactions that reduce the compound's concentration in the lipid can certainly contribute
to these results. However, if these are the only explanations, it is not immediately clear how
compounds can reduce Tat transport (i.e., decrease total mCherry fluorescence) by disrupting
the membrane potential and yet not affect cell growth. The answer may lie in themagnitude of
the Δψ required to support Tat transport. We earlier reported that in vitro E. coli Tat transport
requires a relatively large Δψ, though it is not necessary for the duration of the transport cycle
[7]. Consequently, it is possible that in vivo Tat transport is substantially reduced when the Δψ
is minimally decreased, and yet growth is largely unaffected since it is not as sensitive to the
magnitude of the Δψ.
Compound 18NIH (triclosan; PubChem CID 5564) has antibacterial and antifungal activities
and is found in many commercial products, including soaps, toothpaste, hand and mouth
washes, toys, bedding, and trash bags [42]. Surgical scrubbing with triclosan is effective against
bacterial infections in a hospital setting [43]. Though triclosan has multiple cellular targets, the
primary (high KD) target is the bacterial enzyme enoyl-acyl carrier protein reductase (ENR;
gene FabI), an enzyme required for fatty acid synthesis [44]. Triclosan is bacteriostatic at low
concentrations. At higher concentrations, it is bactericidal and it promotes tumors in liver
[45,46]. We conclude that the inconsistent effects of triclosan on in vitro Tat transport arise
from binding interactions with other target enzymes.
Table 1. IC50's for Hits Surviving the In Vitro Tat Transport Assays.
Compound ID IC50 (μM) (Live Cell Assay) IC50 (μM) (Tat Transport) IC50 (μM) (Δψ)
1JS 6 3 1
51JS 20 12 8
111JS 31 0.7 0.1
181JS 20 1 0.4
202JS 5 11 3
140JS 14 2 1
18NIH 2 ICa > 100b
21NIH 13 50 4
The IC50's obtained for the mCherry ﬂuorescence intensity during in vivo cell growth (column 2), for the
efﬁciency of NADH-dependent in vitro Tat transport (column 3), and for the electrical ﬁeld gradient (column
4) are tabulated for hit compounds that survived both in vitro Tat transport assays (see Fig 10). Sample
results and assay details are provided in S3 Fig. Note that the membrane concentration in the in vitro
transport assays (A280 = 5) was 10-fold higher than in the Δψ assays (A280 = 0.5), and hence, the IC50's are
higher in the former assays since the compounds must partition into the membrane bilayer. Transport
assays require high IMV concentrations in order to observe sufﬁcient transport on gels. Δψ assays require
low IMV concentrations in order to more accurately detect the maximum Δψ before the dissolved oxygen is
consumed [7].
aInconclusive (IC) due to lack of reproducible inhibition of Tat transport (S4A Fig).
bNotably, 18NIH increased the duration of the Δψ (S4B and S4C Fig).
doi:10.1371/journal.pone.0149659.t001
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High throughput screening provides the opportunity to efficiently and cost-effectively test a
large number of diverse small molecules such that at least a few lead compounds that inhibit
the target pathway can be identified even when the “hit” rate is particularly low [47]. The iden-
tification of compounds that bind to transmembrane regions has been especially difficult [48–
50]. Though TatA and TatB have extramembraneous cytoplasmic domains, these are relatively
small and may not have stable secondary and tertiary structures [51]. TatC is predominantly
transmembraneous, with relatively small extramembrane loops [15,18]. In addition, the signal
peptide appears to bind deep within the membrane-spanning protein of the TatBC complex,
rather than at the cytoplasmic surface [52,53]. Thus, the Tat machinery appears to have little
hydrophilic surface area and it is unclear how much of this is important for binding interac-
tions or conformational changes. These reasons may at least partially explain the difficulty with
identifying inhibitors of the Tat machinery. Chemical libraries designed to target transmem-
brane regions may be better suited for identifying Tat machinery drug leads. Alternatively, the
Fig 10. Summary of the HTS's and Hit Analysis by Follow-up Screens. Surviving and eliminated
compounds from the local (left) and BIPDeC (right) HTS's are denoted by black and red numbers,
respectively. The number of eliminated compounds at each step is shown to the right of the arrows and the
number of surviving compounds are shown on the left in bold. Active (123) and inconclusive (1263*)
compounds after the primary BIPDeC HTS were evaluated for chemical intractability and then retested in
dose response and cell growth assays.
doi:10.1371/journal.pone.0149659.g010
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recent X-ray structure of TatC [15,18] suggests that identification of the signal peptide binding
site is forthcoming, which would enable structure-based drug design.
Materials and Methods
Bacterial Strains, Plasmids and Growth Conditions
Plasmids and Tat proteins were as follows. Plasmids pTorA-GFP and pET25-SufI [7] encode
spTorA-GFP-H6 and pre-SufI-H6, respectively, both of which contain C-terminal 6xHis tags.
Plasmid pSufI-IAC [54] encodes a single-cysteine derivative of pre-SufI-H6, and was generated
by mutations C17I and C295A and the addition of a cysteine immediately following the 6xHis
tag (C497). Plasmids pTorA-mCherry-H6 and pTorA-mCherry-SsrA are derivatives of plas-
mid pTorA-GFP [7], and encode spTorA-mCherry-H6 and spTorA-mCherry-SsrA (S1 Fig),
respectively, under the control of the arabinose inducible promoter of pBAD24 (ColE1 origin).
These proteins consist of the TorA (a native Tat substrate) signal peptide (spTorA), mCherry
(a fluorescent cargo protein) and either a 6xHis tag or SsrA-tag (which promotes protein deg-
radation in the cytoplasm by the Clp protease system) [31]. Plasmid pTorA-GFP-SsrA encodes
the protein spTorA-GFP-SsrA, which is identical to the TorA-GFP-SsrA protein reported ear-
lier [31], except that the host vector is the same as for pTorA-mCherry-SsrA described above.
Plasmid pTatABC-Duet1 was constructed by cloning the NcoI-SalI insert from pTatABC [55]
into pACYC-Duet1 (p15A origin). This plasmid encodes the E. coli TatA, TatB and TatC pro-
teins under the control of T7 promoter, and can co-exist with plasmids pTorA-mCherry-H6,
pTorA-mCherry-SsrA, or pTorA-GFP-SsrA. All protein coding regions were confirmed by
DNA sequencing. The three different strain backgrounds used are: ΔTat (MC4100ΔTa-
tABCDE); Tat+ [MC4100(DE3)]; and Tat++ [MC4100(DE3) with pTatABC-Duet1]. E. coli
strains MC4100ΔTatABCDE and MC4100(DE3) were a gift of Tracy Palmer (University of
Dundee), and have been described earlier [56,57].
E. coli strains MC4100(DE3) and JM109 [55,57,58] were used for the HTS and for cloning
purposes, respectively. E. coli cultures were grown using Luria-Bertani (LB) media (Growcells,
Irvine, CA 92618, USA) and were supplemented with ampicillin (Ap, 100 μg/mL; Sigma-
Aldrich Corporation, MO, USA), chloramphenicol (Cm, 34 μg/mL) (USB Corporation, OH,
USA), arabinose (Sigma-Aldrich Corporation, MO, USA), and IPTG (G-Biosciences, MO,
USA) as required for growth and induction, unless otherwise indicated.
Isolation of Arabinose-Resistant Strains
MC4100 is an araDmutant strain, and L-arabinose inhibits its growth. Suppressor mutations
are readily obtained when this strain is grown with arabinose, and these typically yield strains
generating variable levels of overproduced proteins [59]. Therefore, arabinose-resistant Tat+
and Tat++ strains were generated, as described below, to ensure more consistency in protein
overproduction. An arabinose-resistant ΔTat strain was not generated.
E. coli strains MC4100(DE3) (pTatABC-Duet1, pTorA-mCherry-H6) and MC4100(DE3)
(pTatABC-Duet1, pTorA-mCherry-SsrA) were grown in 20 mL LB media supplemented with
Cm and Ap, and shaken (250 rpm) at 37°C until A500 0.5. The cultures were then supple-
mented with 100 mM arabinose, incubated overnight (~15 hours) under the same conditions,
and then serially diluted and plated on LB-agar supplemented with Cm and Ap. After incubat-
ing the plates overnight at 37°C, 6 colonies from each strain were tested for the production and
periplasmic localization of spTorA-mCherry-H6 and spTorA-mCherry-SsrA by in situ gel-fluo-
rescence using a phosphorimager Model FX. For each protein, all colonies exhibited similar pro-
duction and periplasmic localization patterns (data not shown). This approach yielded strains
that overproduce spTorA-mCherry-H6 or spTorA-mCherry-SsrA in the Tat++ background.
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To obtain the Tat+ strain, a plasmid-free version of arabionose-resistant MC4100(DE3)
(pTatABC-Duet1, pTorA-mCherry-SsrA) was obtained as follows. A 10 mL LB culture was
grown overnight (37°C), and then repeatedly (5X) subcultured into fresh 10 mL LB media at a
1:100 ratio every 24 h. The final culture was serially diluted and plated on LB-agar plates and
incubated overnight at 37°C. Colonies were replica-plated on LB-agar plates lacking antibiotics
and plates supplemented with Ap or Cm, respectively. Six antibiotic-insensitive colonies were
chosen, and confirmed to be arabinose-resistant by growth on plates with 100 mM arabinose.
One of these was chosen as the Tat+ strain, which was transformed with pTorA-mCherry-SsrA
to generate a strain that overproduces spTorA-mCherry-SsrA in the Tat+ background.
Cell Fractionation
The cellular location of mCherry proteins was determined by cell fractionation. Cells were
grown overnight in 2 mL LB broth supplemented with appropriate antibiotics at 37°C. These
cultures were diluted 1:50 in 2 mL of fresh media, and growth was continued at 37°C with
shaking (200 rpm) until A500 1.0. Protein production was then induced by arabinose addi-
tion, and cultures were grown at 25°C for 8 h. Cells (1 mL, A500 = 1.0) were fractionated as
described [60]. Both cytoplasmic and periplasmic fractions were suspended in a final volume
of 100 μL in 1x sample buffer (10% glycerol, 2% SDS, 0.01% bromophenol blue, 1.25% β-mer-
captoethanol, 60 mM Tris-Cl, pH 6.8), and a 10 μL fraction was analyzed by SDS-PAGE and
detected by in situ gel-fluorescence using a phosphorimager Model FX (Bio-Rad Laboratories)
[7], or by Western blot analysis.
Imaging mCherry Localization
Imaging of cells expressing various mCherry precursors was performed similar to the approach
described earlier for spTorA-GFP [60]. Strains were grown in 1 mL LB media supplemented
with appropriate antibiotics at 37°C, 250 rpm for 6 h. mCherry Tat precursors were induced
with 2 mM arabinose and cultures were incubated overnight (~15 h, 25°C, 250 rpm). Cells
were harvested (4,000 g for 10 min), and incubated in fresh LB media (2 mL) with antibiotics
but no arabinose for an additional 5 h. The undiluted culture (5 μL) was place on a glass cover-
slip, and covered with a 2 mm thick square of agarose gel (prepared in 17 mMNaCl, 10 mM
Tris, pH 7.0) to immediately immobilize the cells. Cells were imaged with spinning disk confo-
cal microscopy (Yokogawa) using 561 nm excitation on a Zeiss Axiovert 200M microscope
equipped with a 1.46 NA 100X oil-immersion objective (Zeiss alpha PlanApochromat) and a
512x512 EMCCD camera (Andor) [61].
Assays
Isolation of inverted membrane vesicles (IMVs), Western blot analyses and purification of pre-
SufI-IAC were performed as described previously [7,62]. Western blots were performed using
rabbit anti-mCherry antibodies (1:10,000 dilution) in the presence of 0.1% Triton X-100 and
0.1% Tween 20. The pre-SufI-IAC protein was labeled with Atto565 maleimide, and the resul-
tant fluorescent protein, pre-SufI-IACAtto565, was used as a substrate for the in vitro Tat trans-
port assays (A280 = 5.0), as described previously [7,62]. The presence of a Δψ was determined
by measuring oxonol VI fluorescence in presence of Tat+ IMVs (A280 = 0.5), as described previ-
ously [7], except that the translocation buffer lacked BSA. Steady-state fluorescence spectra
and fluorescence intensities of whole cells producing mCherry proteins were determined with
an SLM-8100 spectrofluorometer.
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HTS for 384-Well Plates
A single colony of E. coli strain MC4100(DE3) (pTatABC-DUET1, pTorA-mCherry-SsrA) was
inoculated into a 100 mL LB culture supplemented with Ap and Cm and grown at 37°C with
shaking (250 rpm) overnight. Cells were harvested by centrifugation at 4,000g for 10 min at
room temperature (RT), suspended in 10 mL fresh LB broth supplemented with Ap and Cm,
and the optical density (A500) was determined. Simultaneously, 700 mL LB supplemented
with 100 mM arabinose, 2 mM IPTG, 100 μg/mL Ap and 68 μg/mL Cm was filter-sterilized
(0.22 μm), and then divided into 200 mL (A) and 500 mL (B) portions. Sterile NaSCN (30 mM
final; 1.5 mL of 4 M NaSCN) was added to portion A, and an equal ratio of sterile water was
added to portion B (3.75 mL). Media and cells were transferred to the HTS facility on ice.
A CyBi-Well vario pipetting workstation (CyBio, Jena, Germany) was used to dispense
library compounds and cultures. Library compounds (1 μL) solubilized in DMSO were added
to 384-well black, clear-bottomed plates (Greiner Bio-one, Germany) in columns 3 to 22 (320
wells/plate). For controls, DMSO (1 μL) was added to each well in columns 1, 2, 22 and 23, to
achieve DMSO uniformity across the plate. Both portions of LB media were inoculated with E.
coliMC4100(DE3) (pTatABC-DUET1, pTorA-mCherry-SsrA) from the concentrated stock to
a final A500 = 0.15. The media with 30 mMNaSCN (positive control, or simulated hit) was dis-
pensed into each well of columns 1 and 24 (49 μL each). An equivalent volume of media with-
out NaSCN was dispensed into each well of columns 2 to 23. Columns 2 and 23 lacked NaSCN
and test compounds and served as negative controls. The first 12,800 compounds were
screened at 5 μM (plates 1–40), and the remaining 38,800 compounds were screened at 20 μM
(plates 41–162).
The plates containing cells and dispersed test compounds were grown with shaking (200
rpm) at 25°C for 8 h. Plates were individually mounted, not stacked, on a hollow plastic plat-
form, allowing adequate air circulation. Following the 8 h incubation, plates were transferred
to 4°C for 16 h. Each plate was covered with an empty plate to prevent condensation on the lid.
The overnight incubation was found to improve the signal-to-background ratio. Following the
incubation, plates were read using a BMG Polarstar Omega plate reader (BMG Labtech, Orten-
berg, Germany) to determine optical densities (A500) and mCherry fluorescence intensities
(EX = 584 nm, EM = 620 nm).
HTS for 1536-Well Plates
This assay was performed at the Broad Institute Probe Development Center (BIPDeC; Cam-
bridge, MA), a comprehensive screening center and member of the Molecular Libraries Probe
Production Centers Network (MLPCN). The original 384-well assay was transferred to the
BIPDeC, where the assay was miniaturized and optimized to run in 1536-well plates. Briefly,
an E. coliMC4100(DE3) (pTatABC-Duet1, pTorA-mCherry-SsrA) culture was grown over-
night in liquid LB broth supplemented with Ap and Cm. The culture was harvested, suspended
in 10 mL fresh media, and placed on ice. The optical density of the culture was determined,
and then diluted to A500 = 0.15 with ice cold LB broth supplemented with 100 mM arabinose, 2
mM IPTG, 100 μg/mL Ap and 68 μg/mL Cm. Black, solid bottom, 1536-well assay plates
(Aurora (Brooks), Chelmsford, MA) were previously prepared with compounds in DMSO (7.5
nL) by acoustic transfer (Echo555, LabCyte, Sunnyvale, CA). Positive (LB broth supplemented
with 30 mMNaSCN) and negative (LB broth supplemented with an equivalent volume of
water instead of NaSCN) controls were added (100 nL) to 256 designated control wells. Assay
plates were loaded into an integrated high throughput screening system (HighRes Biosolutions,
Woburn, MA), which performed all the assay steps. The assay was initiated by the addition of
7.5 μL of the induced culture, and then incubated for 8 h at 30°C with shaking at 200 rpm.
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Plates were removed from the incubator, 2.5 μL of 5% glucose was added to each well, and the
plates were returned to the incubator for 4 h. Plates were then incubated at 4°C overnight. At
the completion of the assay, the plates were read on an Envision (PerkinElmer, Waltham, MA)
plate reader to determine the fluorescence intensity. The data were analyzed using Genedata
Assay Analyzer (Lexington, MA), and submitted to PubChem. Following analysis, compounds
from the primary screen were ordered and retested at dose response. Compounds were spotted
on assay plates as previously described, at 8 different concentrations ranging from 40 μM to
0.3 μM, in 2-fold dilutions. These same compounds were also tested in a counter assay designed
to identify non-specific bacterial growth inhibitors, which produce false positive results in the
primary assay. E. coliMC4100(DE3) (pTatABC-Duet1, pTorA-mCherry-SsrA) was cultured
and harvested as done for the primary assay, and then inoculated into fresh LB supplemented
only with Ap and Cm. Compounds were spotted in dose response format on white, solid-bot-
tomed assay plates (Aurora (Brooks), Chelmsford, MA). Kanamycin (40 μg/mL) was added to
144 positive control wells. Cultures were incubated with compounds for 8 h, and then assessed
for viability with Bac-TiterGlo (Promega, Madison, WI). Luminescence was detected with an
Envision plate reader. Data from the dose response experiments were analyzed using Genedata
Assay Analyzer and Condeseo, and submitted to PubChem.
Characteristics of Chemical Libraries
The local library was constructed to ensure diversity among the compounds, guaranteeing that
no pair of compounds had a Tanimoto similarity score [63] greater than 0.7. This approach
minimizes the bias of many existing libraries, which often contain many variations of common
scaffolds. This diversity library was designed by combining structures from catalogs of small
molecules from multiple commercial vendors totaling over 3 million compounds, and selecting
a diverse and representative subset using a clustering algorithm. The compounds were first fil-
tered by Lipinski’s rules to remove non-drug-like compounds, and then compounds with reac-
tive chemotypes or those predicted to be promiscuous aggregators were removed. At the time
of the primary HTS assay, the local library consisted of 51,600 compounds.
The MLSMR collection of compounds is described at: http://mli.nih.gov/mli/compound-
repository/mlsmr-compounds/. At the time of our primary screening, the MLSMR collection
of compounds consisted of 337,881 compounds.
Supporting Information
S1 Fig. Restriction Map and Amino Acid Sequence of spTorA-mCherry-SsrA. The amino
acid sequence of spTorA, mCherry and the SsrA tag are highlighted in yellow, red and green,
respectively. The linker sequence between spTorA and mCherry is highlighted in blue. The par-
ent plasmid was pTorA-GFP [7]. For pTorA-mCherry-H6, the SsrA-tag was replaced with a
6xHis-tag. For pTorA-GFP-SsrA, the mCherry protein was replaced with GFP.
(TIFF)
S2 Fig. Chemical Structures of Hit Compounds that Survived the In VitroNADH-Depen-
dent Tat Transport Assays. (A) [(2-bromophenyl)hydrazono]malononitrile (1JS; PubChem
CID 23273954), (B) 1-chloro-2,4-dinitronaphthalene (51JS; PubChem CID 16987), (C)
N-(4,7-dioxo-2,1,3-benzoxadiazol-5-yl)acetamide (55JS; PubChem CID 610143), (D) 1-
[(2,3,5,6-tetrafluoropyridin-4-yl)amino]-3-[(3-trifluoromethyl)phenyl]thiourea (111JS; Pub-
Chem CID 1825999), (E) 1-(5-nitro-1,3-thiazol-2-yl)-3-[3-(trifluoromethyl)phenyl]urea (181JS;
PubChem CID 4416121), (F) 4-nitro-2-thiophen-2-ylphenol (202JS; PubChem CID 7131469),
(G) 5-[3-(trifluoromethyl)phenyl]isoquinoline (140JS), (H) 5-Chloro-2-(2,4-dichlorophenoxy)
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phenol (18NIH; triclosan; PubChem CID 5564), and (I) 5-[(3,5-dichlorophenyl)methyl]-4,6-
dihydrotriazolo[1,5-a][1,4]benzodiazepine-6-carbonitrile. (NIH21; PubChem CID 44825859).
(TIFF)
S3 Fig. IC50's for Hit Compound 181
JS. These data illustrate how the IC50's summarized in
Table 1 were obtained. (A) The total cellular mCherry fluorescence (live cell assay; n = 1), (B)
the in vitro NADH-dependent Tat transport efficiency of pre-SufI (n = 1), and (C) the maxi-
mum transmembrane electrical potential gradient (n = 1) were measured for a range of concen-
trations of compound 181JS (S2E Fig). (D) SDS-PAGE gel showing in-gel fluorescence data
used in (B). For (A), cells expressing spTorA-mCherry-SsrA were grown under Tat++ condi-
tions in a 384-well plate in the presence of 0, 0.08, 0.15, 0.3, 0.63, 1.25, 2.5, 5, 10, 20, or 40 μM
compound 181JS, as described for the HTS assay (see Methods). For (B) and (C), IMVs were
incubated with the same concentrations of compound 181JS prior to initiation of Tat transport
and Δψ generation by the addition of NADH, as described previously [7]. The red curves are
best-fits using y = d + (100-d)/(1+(x/IC50)
b), where b is a slope factor and d is the high concen-
tration asymptote [64].
(TIFF)
S4 Fig. Characterization of Compound 18NIH. (A) Effect of compound 18NIH (S2H Fig) on in
vitro Tat transport of pre-SufI using NADH (4 mM) to generate a Δψ. Out of 22 independent
assays by three different people, compound 18NIH inhibited Tat transport 12 times. Shown
here are 4 representative assays, the top 2 of which show inhibited transport. For calibration of
transport efficiency, 20 and 40% of the pre-SufI added to the reaction is shown in the leftmost
lanes (Std). A minus NADH control (-) is also shown. (B & C) Effect of compound 18NIH on
the magnitude and duration of the Δψ across the IMV membrane. The top panel (B) demon-
strates that compound 18NIH affected both the magnitude and the duration of the Δψ for the
assayed IMV preparation. The bottom panel (C) summarizes the effect of compound 18NIH on
the duration of the Δψ, the magnitude of the Δψ and in vitro Tat transport (n = 1 for the Δψ val-
ues and n = 3 for in vitro Tat transport using two IMV preparations). These data suggest that
when compound 18NIH does inhibit Tat transport, it does NOT do so by collapsing the Δψ.
However, since compound 18NIH does NOT ALWAYS inhibit Tat transport (see A), direct
binding to (and inhibition of) the Tat machinery does not appear to be the dominating interac-
tion of the compound.
(TIFF)
S5 Fig. Effect of P. aeruginosa Tat Inhibitors on E. coli Cell Growth and Tat Transport. The
concentration-dependent effects of Bay 11–7082 (A) and N-phenylmaleimide (B) on bacterial
growth (black) and in vivo Tat transport of spTorA-mCherry-SsrA (red) was determined under
Tat++ conditions (top). An overnight culture of MC4100(DE3) (pTorA-mCherry-SsrA, pTa-
tABC-Duet1) was diluted 1:50 in 10 mL fresh LB broth with appropriate antibiotics and dis-
pensed (2 mL) into 5 tubes, and growth was continued at 37°C with shaking at 200 rpm until
A500 0.5. The indicated concentrations of the two compounds were added, and the expres-
sion of spTorA-mCherry-SsrA and TatABC were induced. Cultures were grown for another 8
h at 25°C. Cell growth was assayed by A500, and cells (1 mL, A500 = 1.0) were fractionated
into cytoplasmic (C) and periplasmic (P) fractions as described [60]. Transport of spTorA-
mCherry-SsrA was assayed by in-gel fluorescence of mCherry (upper gels) and Western blot
analyses (middle gels). The quantified in vivo transport of spTorA-mCherry-SsrA is an average
of the in-gel mCherry fluorescence and the Western blot analysis. The mature mCherry-SsrA
in the periplasmic fraction of cells grown in the absence of a putative inhibitor was set to 100%.
In vitro Tat transport assays in the presence of 2.5 mM DTT (bottom gels) were performed
High-Throughput Screening for Tat Inhibitors
PLOS ONE | DOI:10.1371/journal.pone.0149659 February 22, 2016 21 / 25
with 90 nM pre-SufI and reactions were initiated with NADH [7]. Control assays performed in
the absence of NADH are identified (-). In the left set of experiments (I), the putative inhibitors
were treated with DTT prior to addition of IMVs and pre-SufI. In the right set of experiments
(II), IMVs were pre-incubated with the putative inhibitors prior to addition of pre-SufI and
DTT. Transport assays performed with and without DTT (bottom; IMVs pre-incubated with
compounds for 5 min prior to SufI and NADH addition) demonstrate that both DTT reacted
and unreacted forms of the two compounds do not inhibit E. coli Tat transport.
(TIFF)
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